Table 1 Baseline characteristics at the start of first TNF inhibitor
From: Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis
Parameter | n = 624 | All Patients n = 624 | BMI category | ||
|---|---|---|---|---|---|
Normal n = 332 | Overweight n = 204 | Obese n = 88 | |||
BMI | 624 | 25.4 (4.3) | 22.3 (1.7) | 27.0 (1.4)* | 33.2 (3.2)* # |
Male sex, % | 624 | 62.2 | 55.7 | 73.5* | 60.2 |
mNYc positive, % | 437 | 73.9 | 73.1 | 75.2 | 74.1 |
Age, years | 624 | 39.4 (11.6) | 37.4 (11.3) | 41.1 (11.7)* | 43.2 (10.5)* |
Symptom duration, years | 619 | 13.0 (10.9) | 12.2 (10.3) | 13.6 (11.7) | 14.5 (11.0) |
HLA-B27 positive, % | 571 | 78.1 | 80.5 | 77.2 | 70.9 |
BASDAI | 549 | 5.5 (1.9) | 5.3 (2.0) | 5.6 (1.9) | 6.1 (1.7)* |
BASDAI Question 1 | 556 | 6.0 (2.3) | 5.8 (2.3) | 6.1 (2.2) | 6.1 (2.0) |
BASDAI Question 2 | 555 | 6.7 (2.3) | 6.5 (2.4) | 6.9 (2.2) | 7.0 (2.1) |
BASDAI Question 3 | 553 | 4.2 (3.0) | 3.9 (3.0) | 4.4 (3.0) | 5.4 (2.8)* |
BASDAI Question 4 | 556 | 5.2 (3.0) | 5.1 (3.1) | 5.2 (3.0) | 5.8 (2.9) |
BASDAI Question 5 | 554 | 6.1 (2.7) | 5.9 (2.7) | 6.3 (2.5) | 6.6 (2.8) |
BASDAI Question 6 | 554 | 4.9 (2.9) | 4.9 (3.0) | 4.8 (2.8) | 5.3 (2.7) |
Patient GA | 552 | 6.4 (2.3) | 6.2 (2.5) | 6.6 (2.2) | 6.6 (2.0) |
Physician GA | 600 | 4.9 (1.9) | 4.9 (1.8) | 4.9 (1.8) | 5.2 (2.0) |
ASDAS | 517 | 3.5 (0.9) | 3.4 (0.9) | 3.5 (0.9) | 3.7 (0.9) |
CRP (mg/l) | 584 | 15.1 (20.0) | 15.3 (19.0) | 14.0 (20.1) | 16.9 (23.4) |
Elevated CRP, % | 581 | 53.4 | 54.8 | 50.0 | 55.4 |
BASFI | 555 | 4.1 (2.5) | 3.7 (2.4) | 4.2 (2.4) | 5.0 (2.6)* |
BASMI, median (IQR) | 540 | 2 (1–3) | 2 (1–3) | 2 (1–3) | 2 (1–4) |
EQ-5D | 540 | 56.2 (20.9) | 58.3 (20.7) | 54.7 (20.8) | 51.8 (21.2)* |
Peripheral arthritis, % | 606 | 34.2 | 32.9 | 35.9 | 34.9 |
Current enthesitis, % | 605 | 71.9 | 69.1 | 71.7 | 82.8 |
Modified MASES, median (IQR) | 599 | 2 (0–4) | 1 (0–4) | 2 (0–4) | 4 (2–6)*# |
Dactylitis ever, % | 616 | 10.2 | 8.3 | 12.2 | 12.9 |
Uveitis ever, % | 555 | 22.2 | 26.4 | 17.4 | 17.7 |
Psoriasis ever, % | 478 | 12.3 | 13.0 | 10.6 | 14.3 |
Current smokers, % | 527 | 36.4 | 39.2 | 31.2 | 38.2 |
Education, high, % | 594 | 84.0 | 86.8 | 81.9 | 78.0 |
Exercise score†, median (IQR) | 500 | 2.0 (0.0–4.0) | 2.0 (0.0–4.0) | 2.0 (0.0–3.0) | 1.5 (0.0–3.0) |
On NSAIDs, % | 565 | 92.2 | 92.8 | 91.6 | 91.4 |
On DMARDs, % | 624 | 12.5 | 11.2 | 13.2 | 15.9 |
On steroids, % | 624 | 9.5 | 10.2 | 7.8 | 10.2 |
First TNFi used | 624 | ||||
Adalimumab, % | 34.5 | 35.8 | 36.3 | 25.0 | |
Certolizumab, % | <0.1 | 0.3 | 1.0 | 0.0 | |
Etanercept, % | 26.7 | 24.4 | 28.9 | 28.4 | |
Golimumab, % | 16.9 | 17.2 | 14.2 | 21.6 | |
Infliximab, % | 21.9 | 22.3 | 19.6 | 25.0 | |